You have 9 free searches left this month | for more free features.

Neoplasms, Plasma Cell

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial in Wuhan (CAR-T (CAR-GPRC5D))

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia
  • CAR-T (CAR-GPRC5D)
  • Wuhan, Hu Bei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
May 17, 2022

Plasma Cell Tumor Trial in Atlanta (Pneumococcal 13-valent Conjugate Vaccine, Trivalent Influenza Vaccine)

Active, not recruiting
  • Plasma Cell Neoplasm
  • Pneumococcal 13-valent Conjugate Vaccine
  • Trivalent Influenza Vaccine
  • Atlanta, Georgia
  • +1 more
Jan 24, 2022

Multiple Myeloma, Plasma Cell Tumor, Malignant Plasma Cell Tumor Trial in Houston (Radiation Therapy)

Recruiting
  • Multiple Myeloma
  • +2 more
  • Radiation Therapy
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Multiple Myeloma Trial in Wuhan (Plasma-free procedure)

Completed
  • Multiple Myeloma
  • Plasma-free procedure
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Feb 10, 2022

Multiple Myeloma, Amyloidosis, Cryoglobulinemia Trial in Chapel Hill

Recruiting
  • Multiple Myeloma
  • +8 more
    • Chapel Hill, North Carolina
      North Carolina Cancer Hospital
    Nov 30, 2021

    A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

    Recruiting
    • Multiple Myeloma
    • +11 more
    • No intervention
    • Beijing, China
      Peking University First Hospital
    Apr 21, 2022

    Immunophenotyping of Plasma Cells and Immune Effector Cells in

    Not yet recruiting
    • Multiple Myeloma
    • Biological sampling
    • (no location specified)
    Jun 17, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Capivasertib)

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Jun 28, 2022

    Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor Trial in Miami (T-cell Receptor a/ß Depleted Donor Lymphocyte

    Recruiting
    • Lymphoid Leukemia, Acute
    • +2 more
    • T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
    • Miami, Florida
      Miami Cancer Institute at Baptist Health, Inc
    May 24, 2022

    Lymphoma, Leukemia, Plasma Cell Dyscrasia Trial in San Francisco (Web Application)

    Not yet recruiting
    • Lymphoma
    • +2 more
    • Web Application
    • San Francisco, California
      University of California, San Francisco
    Aug 9, 2022

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Laboratory Biomarker Analysis, Lenalidomide,

    Completed
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Laboratory Biomarker Analysis
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic
    Dec 1, 2021

    Plasma Cell Myeloma Trial in United States (Lenalidomide)

    Active, not recruiting
    • Plasma Cell Myeloma
    • Basking Ridge, New Jersey
    • +5 more
    Sep 1, 2021

    Based on Maintenance Therapy Post Autologous Stem Cell

    Recruiting
    • Multiple Myeloma
    • Autologous Stem Cell Transplant
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    Jul 27, 2022

    Multiple Myeloma Trial in Saint Petersburg (Melphalan, Nivolumab, Autologous Stem Cell Transplantation)

    Recruiting
    • Multiple Myeloma
    • Saint Petersburg, Russian Federation
      Boris V Afanasyev, MD, Prof.
    Apr 4, 2022

    Tumor, Plasma Cell, Lymphoma Trial in Toulouse (Comprehensive Geriatric Assessment)

    Not yet recruiting
    • Neoplasm, Plasma Cell
    • Lymphoma
    • Comprehensive Geriatric Assessment
    • Toulouse, France
      University Hospital Toulouse
    May 17, 2022

    Multiple Myeloma, Tumors, Tumors, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide)

    Not yet recruiting
    • Multiple Myeloma
    • +7 more
    • Belantamab Mafodotin-Blmf
    • +3 more
    • (no location specified)
    Mar 4, 2022

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Laboratory Biomarker Analysis, Leflunomide,

    Active, not recruiting
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Laboratory Biomarker Analysis
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Oct 4, 2021

    The Indiana Myeloma Registry

    Recruiting
    • Plasma Cell Dyscrasias
    • This is a non-interventional trial
    • Indianapolis, Indiana
      Indiana University Simon Cancer Center
    Mar 2, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Trametinib

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Trametinib Dimethyl Sulfoxide
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Aug 13, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Defactinib

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Defactinib Hydrochloride
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Jun 28, 2022

    Recurrent Plasma Cell Myeloma Trial in Houston (Daratumumab)

    Recruiting
    • Recurrent Plasma Cell Myeloma
    • Daratumumab
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 22, 2021

    Multiple Myeloma, Plasma Cell Disorder Trial in Germany, United States (HDP-101)

    Recruiting
    • Multiple Myeloma
    • Plasma Cell Disorder
    • Atlanta, Georgia
    • +5 more
    Mar 10, 2022

    Myeloma Multiple Trial (Traditional Control, Oral Nutritional Supplement)

    Not yet recruiting
    • Myeloma Multiple
    • Traditional Control
    • Oral Nutritional Supplement
    • (no location specified)
    Jul 12, 2022

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

    Recruiting
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Jun 14, 2022

    Multiple Myeloma Trial (REGN5458)

    Available
    • Multiple Myeloma
    • (no location specified)
    Dec 9, 2021